{rfName}

Indexed in

License and Use

Icono OpenAccess

Citations

279

Altmetrics

Analysis of institutional authors

Veny, MarisolAuthorSalas AAuthorAbraham CAuthor

Share

April 19, 2023
Publications
>
Review
Sí

IL-12 and IL-23 pathway inhibition in inflammatory bowel disease

Publicated to: Nature Reviews Gastroenterology & Hepatology. 20 (7): 433-446 - 2023-07-01 20(7), DOI: 10.1038/s41575-023-00768-1

Authors: Verstockt, B; Salas, A; Sands, BE; Abraham, C; Leibovitzh, H; Neurath, MF; Vande Casteele, N

Affiliations

Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. - Author
Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Inflammatory Bowel Dis Unit - Author
Icahn Sch Med Mt Sinai, Dr Henry D Janowitz Div Gastroenterol - Author
Katholieke Univ Leuven, Translat Res Ctr Gastrointestinal Disorders TARGI, Dept Chron Dis & Metab - Author
NULL - Author
Univ Calif San Diego, Dept Med - Author
Univ Erlangen Nurnberg, Deutsch Zentrum Immuntherapie DZI - Author
Univ Toronto, Mt Sinai Hosp, Temerty Fac Med, Zane Cohen Ctr Digest Dis,Div Gastroenterol & Hep, Toronto - Author
Yale Univ, Dept Med - Author
See more

Abstract

Interleukin-12 (IL-12) and interleukin-23 (IL-23), which belong to the IL-12 family of cytokines, have a key role in intestinal homeostasis and inflammation and are implicated in the pathogenesis of inflammatory bowel disease. Upon their secretion by antigen-presenting cells, they exert both pro-inflammatory and anti-inflammatory receptor-mediated effects. An increased understanding of these biological effects, particularly the pro-inflammatory effects mediated by IL-12 and IL-23, has led to the development of monoclonal antibodies that target a subunit common to IL-12 and IL-23 (p40; targeted by ustekinumab and briakinumab), or the IL-23-specific subunit (p19; targeted by risankizumab, guselkumab, brazikumab and mirikizumab). This Review provides a summary of the biology of the IL-12 family cytokines IL-12 and IL-23, discusses the role of these cytokines in intestinal homeostasis and inflammation, and highlights IL-12- and IL-23-directed drug development for the treatment of Crohn’s disease and ulcerative colitis. © 2023, Springer Nature Limited.

Keywords

Biological markerBiologyBrazikumabBriakinumabCrohn diseaseCytokine receptor antagonistDisease severityDrug safetyDrug targetingGuselkumabHomeostasisHumanHumansInflammationInflammatory bowel diseaseInterleukin 12Interleukin 12 antibodyInterleukin 12p40Interleukin 23Interleukin 23 antibodyInterleukin 23p19Interleukin signalingInterleukin-12Interleukin-23MirikizumabNonhumanPathogenesisPersonalized medicineProtein functionReviewRisankizumabUlcerative colitisUstekinumab

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Nature Reviews Gastroenterology & Hepatology due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2023, it was in position 1/143, thus managing to position itself as a Q1 (Primer Cuartil), in the category Gastroenterology & Hepatology. Notably, the journal is positioned above the 90th percentile.

This publication has been distinguished as a “Highly Cited Paper” by the agencies WoS (ESI, Clarivate) and ESI (Clarivate), meaning that it ranks within the top 1% of the most cited articles in its thematic field during the year of its publication. In terms of the observed impact of the contribution, this work is considered one of the most influential worldwide, as it is recognized as highly cited. (source consulted: ESI Nov 13, 2025)

And this is evidenced by the extremely high normalized impacts through some of the main indicators of this type, which, although dynamic over time and dependent on the set of average global citations at the time of calculation, already indicate that they are well above the average in different agencies:

  • Normalization of citations relative to the expected citation rate (ESI) by the Clarivate agency: 24.95 (source consulted: ESI Nov 13, 2025)
  • Weighted Average of Normalized Impact by the Scopus agency: 11.96 (source consulted: FECYT Mar 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-12-15, the following number of citations:

  • WoS: 136
  • Scopus: 61
  • Europe PMC: 3

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-12-15:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 163.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 162 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 33.
  • The number of mentions on the social network Facebook: 1 (Altmetric).
  • The number of mentions on the social network X (formerly Twitter): 37 (Altmetric).
  • The number of mentions in news outlets: 1 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: Belgium; Canada; Germany; Italy; Netherlands; United States of America.